Download PDF
J Pediatr Intensive Care 2020; 09(02): 139-140
DOI: 10.1055/s-0039-1700951
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

Nagehan Aslan 
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Dincer Yildizdas
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Behruz Huseyınlı
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ozden Ozgur Horoz
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Gulen Gul Mert
2   Department of Pediatrics, Division of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey
,
Faruk Ekinci
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Duygu Ozcanyuz
2   Department of Pediatrics, Division of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey
› Author Affiliations
Further Information

Publication History

09 October 2019

23 November 2019

Publication Date:
14 January 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Etiology of rhabdomyolysis includes hereditary muscle enzyme deficiencies, trauma, viral infections, excessive exercise, hypothyroidism, and medications such as colchicine, lithium, and statins. Several studies have reported that various antiepileptic drugs may induce rhabdomyolysis. Levetiracetam is one of the antiepileptic drugs implicated in the etiology of rhabdomyolysis. Herein, we present a case of rhabdomyolysis in an adolescent treated with levetiracetam. We wanted to draw attention to the increasing trend of levetiracetam-associated rhabdomyolysis frequency in pediatric patients.

Keywords

adolescent - rhabdomyolysis - levetiracetam
 

  • References

  • 1 Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988; 148 (07) 1553-1557
    CrossrefPubMedSearch in Google Scholar
  • 2 Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84 (06) 377-385
    PubMedSearch in Google Scholar
  • 3 Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. Med J Aust 2013; 199 (09) 624-625
    CrossrefPubMedSearch in Google Scholar
  • 4 Santos-Calle FJ, Borrás-Blasco J, Navarro-Ruiz A, Plaza Macias I. Unsuspected rhabdomyolysis associated with phenytoin. Int J Clin Pharmacol Ther 2005; 43 (09) 436-440
    CrossrefPubMedSearch in Google Scholar
  • 5 Incecik F, Herguner OM, Besen S, Altunbasak S. Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta Neurol Belg 2016; 116 (03) 369-370
    CrossrefPubMedSearch in Google Scholar
  • 6 Carnovale C, Gentili M, Antoniazzi S, Clementi E, Radice S. Levetiracetam-induced rhabdomyolysis: analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database. Muscle Nerve 2017; 56 (06) E176-E178
    PubMedSearch in Google Scholar
  • 7 Grifoni E, Fabbri A, Ciuti G, Matucci Cerinic M, Moggi Pignone A. Hypokalemia-induced rhabdomyolysis. Intern Emerg Med 2014; 9 (04) 487-488
    CrossrefPubMedSearch in Google Scholar
  • 8 Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy Behav Case Rep 2014; 2: 152-155
    PubMedSearch in Google Scholar
  • 9 Isaacson JE, Choe DJ, Doherty MJ. Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy Behav Case Rep 2014; 2: 189-191
    PubMedSearch in Google Scholar
  • 10 Singh R, Patel DR, Pejka S. Rhabdomyolysis in a hospitalized 16-year-old boy: a rarely reported underlying cause. Case Rep Pediatr 2016; 2016: 7873813
    PubMedSearch in Google Scholar